Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease

被引:5
|
作者
Williams, Adam N. [1 ,2 ,3 ]
机构
[1] Bend Mem Clin, Dept Allergy Asthma & Immunol, 815 Southwest Bond St, Bend, OR 97702 USA
[2] Oregon Hlth & Sci Univ, Sch Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA
[3] Bend Mem Clin, 815 Southwest Bond St, Bend, OR 97702 USA
关键词
Aspirin-exacerbated respiratory disease; Diagnosis; NSAID hypersensitivity; Chronic rhinosinusitis with nasal polyps; Asthma; Intranasal ketorolac; Oral aspirin challenge; Lysine-aspirin; PERIPHERAL-BLOOD LEUKOCYTES; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LEUKOTRIENE-MODIFIER DRUGS; NASAL PROVOCATION TEST; IN-VITRO DIAGNOSIS; INDUCED ASTHMA; SENSITIVE ASTHMATICS; BASOPHIL ACTIVATION; CYSTEINYL LEUKOTRIENES; LYSINE-ASPIRIN;
D O I
10.1016/j.iac.2016.06.003
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Aspirin-exacerbated respiratory disease (AERD) is a distinct clinical condition characterized by chronic sinusitis with nasal polyps, asthma, and hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). Distinguishing AERD from other forms of chronic sinusitis, asthma, and NSAID reactivity has important clinical implications for management. The clinical history is helpful, but not adequate for confirming the diagnosis of AERD, in most cases. Diagnostic provocation challenge remains the only way to confirm or exclude the diagnosis of AERD. This article discusses the utility of the clinical history and the current evidence regarding measures that optimize the safety of performing diagnostic NSAID provocation challenges.
引用
收藏
页码:657 / +
页数:14
相关论文
共 50 条
  • [31] Cellular interactions in aspirin-exacerbated respiratory disease
    Badrani, Jana H.
    Doherty, Taylor A.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 21 (01) : 65 - 70
  • [32] Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease
    Luskin, Kathleen
    Thakrar, Hiral
    White, Andrew
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2020, 40 (02) : 329 - +
  • [33] Approach to desensitization in aspirin-exacerbated respiratory disease
    Scott, David R.
    White, Andrew A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 112 (01) : 13 - 17
  • [34] Mast Cells in Aspirin-Exacerbated Respiratory Disease
    Abud, Edsel M.
    White, Andrew A.
    CURRENT ALLERGY AND ASTHMA REPORTS, 2024, 24 (02) : 73 - 80
  • [35] An update on the epidemiology of aspirin-exacerbated respiratory disease
    White, Andrew A.
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2017, 31 (05) : 299 - 301
  • [36] AN "EXCEPTIONAL" ASPIRIN-EXACERBATED RESPIRATORY DISEASE PATIENT
    Thakrar, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S134 - S134
  • [37] Perimenstrual Asthma in Aspirin-Exacerbated Respiratory Disease
    Eid, Ryan C.
    Palumbo, Marina L.
    Cahill, Katherine N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02): : 573 - +
  • [38] Omalizumab in the treatment of aspirin-exacerbated respiratory disease
    Bergmann, Karl-Christian
    Zuberbier, Torsten
    Church, Martin K.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (03): : 459 - 460
  • [39] Clinical updates in aspirin-exacerbated respiratory disease
    Laidlaw, Tanya M.
    ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (01) : 70 - 70
  • [40] Aspirin-exacerbated respiratory disease: is it in our DNA?
    Chang, Jinny
    Simon, Ronald A.
    Stevenson, Donald D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 106 (04) : 263 - 264